and MTX combination therapy (PICO 32) Very low Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-17i biologic and MTX combination therapy in patients with concomitant uveitis, as uveitis may respond to MTX therapy. 12/23i biologic in patients with recurrent or serious infections. To facitinib may be considered instead of an IL-17i biologic in patients who prefer oral therapy or have a history of recurrent or severe Candida infections. Tofacitinib may